JP2023529365A5 - - Google Patents
Info
- Publication number
- JP2023529365A5 JP2023529365A5 JP2022574520A JP2022574520A JP2023529365A5 JP 2023529365 A5 JP2023529365 A5 JP 2023529365A5 JP 2022574520 A JP2022574520 A JP 2022574520A JP 2022574520 A JP2022574520 A JP 2022574520A JP 2023529365 A5 JP2023529365 A5 JP 2023529365A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067272A JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063034214P | 2020-06-03 | 2020-06-03 | |
| US63/034,214 | 2020-06-03 | ||
| PCT/US2020/050753 WO2021247064A1 (en) | 2020-06-03 | 2020-09-14 | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067272A Division JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529365A JP2023529365A (ja) | 2023-07-10 |
| JP2023529365A5 true JP2023529365A5 (cg-RX-API-DMAC10.html) | 2023-09-22 |
| JP7669396B2 JP7669396B2 (ja) | 2025-04-28 |
Family
ID=72659928
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574520A Active JP7669396B2 (ja) | 2020-06-03 | 2020-09-14 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
| JP2025067272A Pending JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067272A Pending JP2025111539A (ja) | 2020-06-03 | 2025-04-16 | 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ |
Country Status (23)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251457T1 (hr) * | 2020-06-03 | 2026-01-02 | Incyte Corporation | Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi |
| EP4297750A1 (en) * | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| WO2024039883A2 (en) * | 2022-08-19 | 2024-02-22 | Translational Drug Development Llc | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |
| WO2024144258A1 (ko) * | 2022-12-28 | 2024-07-04 | 주식회사 삼양홀딩스 | 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법 |
| EP4734995A1 (en) * | 2023-06-28 | 2026-05-06 | Board of Regents, The University of Texas System | Quinoline carboxamides for use in the treatment of mpn |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| SMT202000133T1 (it) * | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| CN109715625B (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| HRP20251457T1 (hr) * | 2020-06-03 | 2026-01-02 | Incyte Corporation | Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi |
-
2020
- 2020-09-14 HR HRP20251457TT patent/HRP20251457T1/hr unknown
- 2020-09-14 MA MA59868A patent/MA59868B1/fr unknown
- 2020-09-14 EP EP20781202.5A patent/EP4161528B1/en active Active
- 2020-09-14 WO PCT/US2020/050753 patent/WO2021247064A1/en not_active Ceased
- 2020-09-14 SI SI202030684T patent/SI4161528T1/sl unknown
- 2020-09-14 RS RS20251189A patent/RS67440B1/sr unknown
- 2020-09-14 IL IL298200A patent/IL298200A/en unknown
- 2020-09-14 DK DK20781202.5T patent/DK4161528T3/da active
- 2020-09-14 PT PT207812025T patent/PT4161528T/pt unknown
- 2020-09-14 EP EP25209713.4A patent/EP4691563A3/en active Pending
- 2020-09-14 ES ES20781202T patent/ES3058891T3/es active Active
- 2020-09-14 KR KR1020227046429A patent/KR20230031242A/ko active Pending
- 2020-09-14 MD MDE20230400T patent/MD4161528T2/ro unknown
- 2020-09-14 FI FIEP20781202.5T patent/FI4161528T3/fi active
- 2020-09-14 CA CA3184633A patent/CA3184633A1/en active Pending
- 2020-09-14 MX MX2022015220A patent/MX2022015220A/es unknown
- 2020-09-14 PL PL20781202.5T patent/PL4161528T3/pl unknown
- 2020-09-14 SM SM20260021T patent/SMT202600021T1/it unknown
- 2020-09-14 LT LTEPPCT/US2020/050753T patent/LT4161528T/lt unknown
- 2020-09-14 JP JP2022574520A patent/JP7669396B2/ja active Active
- 2020-09-14 PH PH1/2022/553276A patent/PH12022553276A1/en unknown
- 2020-09-14 AU AU2020451061A patent/AU2020451061A1/en active Pending
- 2020-09-14 CN CN202080101656.6A patent/CN115835868A/zh active Pending
-
2022
- 2022-12-01 CL CL2022003409A patent/CL2022003409A1/es unknown
-
2025
- 2025-04-16 JP JP2025067272A patent/JP2025111539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3007386T3 (en) | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| US6602868B2 (en) | Treatments for restless legs syndrome | |
| JP2024507938A5 (cg-RX-API-DMAC10.html) | ||
| TW200918073A (en) | Heterocyclus-substituted piperazino-dihydrothienopyrimidines | |
| ES2913097T3 (es) | Uso de derivados de quinolina para el tratamiento del cáncer de esófago y método de tratamiento, composición farmacéutica y equipo de los mismos | |
| JP2017516784A (ja) | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 | |
| JP2021523220A5 (cg-RX-API-DMAC10.html) | ||
| JP5693970B2 (ja) | ベンゾフェナントリジン構造を有する抗腫瘍薬およびそれらを含有する製剤 | |
| BR112020019134A2 (pt) | produtos de combinação que compreendem inibidor de bcl-2 e mab anti-cd20, ou inibidor de bcl-2, mab anti-cd20 e bendamustina, ou inibidor de bcl-2 e chop e usos terapêuticos dos mesmos | |
| JP2023546362A5 (cg-RX-API-DMAC10.html) | ||
| TW201927290A (zh) | 雙層醫藥錠劑調配物 | |
| FI4161528T3 (fi) | Ruksolitinibin ja incb057643:n yhdistelmä käytettäväksi myeloproliferatiivisten kasvainten hoidossa | |
| JP4610481B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| US11453664B2 (en) | Thymoquinone/harmaline and related reaction products | |
| US11453665B2 (en) | Thymoquinone/harmaline and related reaction products | |
| WO2024015851A1 (en) | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent | |
| US20200101050A1 (en) | Thymoquinone/harmaline and related reaction products | |
| TW200838537A (en) | Substituted quinazolines | |
| TW200410698A (en) | Methods of treating patients suffering from restless legs syndrome or related disorders | |
| CN117417281A (zh) | 抗炎、抗癌和抗血管生成化合物，药物组合物及其制备和使用方法 | |
| CN109415382A (zh) | 皮质抑素类似物 | |
| JP2004533434A (ja) | テガフール、ウラシル、フォリン酸およびシクロホスファミドの投与による腫瘍の治療方法 | |
| CN113543779A (zh) | 使用6,8-双-苄硫基-辛酸的口服疗法 | |
| CN111777621B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| CN105017281A (zh) | 一类安妥沙星的盐及其制备方法和用途 |